5 Stocks Dragging The Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.4%) at 15,601 as of Monday, Aug. 5, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,233 issues advancing vs. 1,686 declining with 120 unchanged.

The Health Services industry currently sits up 0.9% versus the S&P 500, which is down 0.2%. Top gainers within the industry include Tenet Healthcare ( THC), up 4.1%, Humana ( HUM), up 1.6%, Cigna ( CI), up 1.4%, Express Scripts ( ESRX), up 0.9% and Medtronic ( MDT), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Grifols ( GRFS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.18 (-0.6%) to $32.79 on light volume. Thus far, 74,332 shares of Grifols exchanged hands as compared to its average daily volume of 625,300 shares. The stock has ranged in price between $32.46-$33.01 after having opened the day at $32.99 as compared to the previous trading day's close of $32.97.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $18.1 billion and is part of the health care sector. Shares are up 25.8% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, ResMed ( RMD) is down $0.66 (-1.4%) to $47.23 on average volume. Thus far, 470,744 shares of ResMed exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $47.17-$48.25 after having opened the day at $48.00 as compared to the previous trading day's close of $47.89.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $6.9 billion and is part of the health care sector. Shares are up 15.2% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate ResMed a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full ResMed Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Catamaran ( CTRX) is down $0.53 (-0.9%) to $57.70 on light volume. Thus far, 580,481 shares of Catamaran exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $57.07-$58.18 after having opened the day at $57.80 as compared to the previous trading day's close of $58.23.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $11.7 billion and is part of the health care sector. Shares are up 21.1% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Catamaran a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, compelling growth in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Catamaran Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Agilent Technologies ( A) is down $0.48 (-1.1%) to $45.90 on light volume. Thus far, 893,748 shares of Agilent Technologies exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $45.86-$46.40 after having opened the day at $46.26 as compared to the previous trading day's close of $46.38.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $15.9 billion and is part of the health care sector. Shares are up 13.3% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Boston Scientific ( BSX) is down $0.07 (-0.6%) to $11.17 on light volume. Thus far, 5.3 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 19.5 million shares. The stock has ranged in price between $11.12-$11.38 after having opened the day at $11.16 as compared to the previous trading day's close of $11.24.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $15.0 billion and is part of the health care sector. Shares are up 96.2% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Boston Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Bank of America, Tariffs and the Goldman Sachs CEO Change: Jim Cramer Rewind

Bank of America, Tariffs and the Goldman Sachs CEO Change: Jim Cramer Rewind

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

Don't Panic! The Risk of a Recession This Year Is Low

Don't Panic! The Risk of a Recession This Year Is Low